Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994


Nunes, Raquel A., Xiaochun Li, Soonmo Peter Kang, Harold Burstein, Lisa Roberts, Walter Carney, Kimberly Blackwell, et al. “Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy.” Int J Biol Markers 24, no. 1 (January 2009): 1–10.

Full Text

Craciunescu, Oana I., Kimberly L. Blackwell, Ellen L. Jones, James R. Macfall, Daohai Yu, Zeljko Vujaskovic, Terence Z. Wong, et al. “DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.” Int J Hyperthermia 25, no. 6 (2009): 405–15.

Full Text

Anders, C., P. K. Marcom, B. Peterson, L. Gu, S. Unruhe, R. Welch, P. Lyons, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer (Cancer Investigation 26, 3, (286-295)).” Cancer Investigation 26, no. 10 (December 1, 2008).

Full Text

Anders, Carey K., David S. Hsu, Gloria Broadwater, Chaitanya R. Acharya, John A. Foekens, Yi Zhang, Yixin Wang, et al. “Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.” J Clin Oncol 26, no. 20 (July 10, 2008): 3324–30.

Full Text

Burstein, H. J., A. M. Storniolo, S. Franco, J. Forster, S. Stein, S. Rubin, V. M. Salazar, and K. L. Blackwell. “A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.” Ann Oncol 19, no. 6 (June 2008): 1068–74.

Full Text

Anders, Carey, P Kelly Marcom, Bercedis Peterson, Lin Gu, Sue Unruhe, Renee Welch, Peggy Lyons, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.” Cancer Invest 26, no. 3 (April 2008): 286–95.

Full Text

Johnston, Stephen, Maureen Trudeau, Bella Kaufman, Hamouda Boussen, Kimberley Blackwell, Patricia LoRusso, Donald P. Lombardi, et al. “Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 26, no. 7 (March 2008): 1066–72.

Full Text

Herold, Christina I., and Kimberly L. Blackwell. “Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.” Clin Breast Cancer 8, no. 1 (February 2008): 50–64.

Full Text